What if obesity was never about willpower? Dr. Matthias Tschöp, President of LMU Munich, co-discovered ghrelin and the hormone science behind Ozempic, Mounjaro, and retatrutide. This episode explains how GLP-1 weight loss drugs actually work, why obesity is now understood as a brain disease rather than a failure of willpower, and what comes next for anti-obesity medication, for anyone trying to understand the science behind the biggest medical story in a generation. This conversation covers the 1994 discovery of leptin, the 2000 discovery of ghrelin in the stomach, how Tschöp’s lab combined GLP-1, GIP, and glucagon into single molecules to build the drugs behind Mounjaro and retatrutide, the real risks of muscle loss and unregulated peptide use, and why these drugs may curb cravings for alcohol and nicotine as well as food. Questions this episode answers: How does Ozempic actually work, and why does it work at all Why was the hunger hormone ghrelin found in the stomach instead of the brain Is obesity really a brain disease, not a failure of willpower What is retatrutide, and how is it different from semaglutide What happens when you stop taking Ozempic or similar drugs Is the muscle loss on these drugs the drug’s fault Chapters: 0:00 Intro 4:36 The 1994 leptin discovery that started the field 10:43 Hunting the hunger hormone and finding it in the stomach, not the brain 12:00 Ghrelin confirmed: the textbook hunger hormone 13:55 Why genetics forced science to call obesity a brain disease 28:10 2011: the GIP/GLP-1 combination behind today's leading drugs 34:02 The number nobody thought possible: ~29-30% weight loss 36:44 Why he's building a version with no GLP-1 at all 38:25 Early results: same weight loss, none of the side effects 40:45 The addiction angle: food, alcohol, nicotine, even gambling 42:13 Does blunting hunger blunt joy? What the data actually shows 45:36 The muscle-loss problem, and why it's not the drug's fault 50:23 Could microdosing become preventive medicine? 56:05 Unregulated peptides, black-market vials, and why that's dangerous 1:08:11 Whether Dr. Tschöp has tried the drug himself 1:19:00 The far future: could GLP-1 treatments become a one-time gene therapy? Dr. Tschöp has spent three decades on this research, from the original 2000 ghrelin paper through the dual and triple agonist science behind today’s leading drugs, published across Nature, Nature Medicine, and Science Translational Medicine. This conversation draws on that firsthand research record, not secondhand reporting on it. Resources mentioned The WNDR Lab Connect with Dr. Matthias Tschöp Connect with our host Chris Wharton Follow The LIVING Room Podcast on Socials: Instagram: @the.Living.room.pod TikTok: https: @the.living.room.pod LinkedIn: The LIVING Room Podcast If you liked this episode, you’ll probably like our episode with Zachary A. Knight, "A Neuroscientist Breaks Down GLP–1s, Genetics & the Real Science of Fat Loss" About this channel The LIVING Room Podcast, hosted by Chris Wharton and part of The WNDR Lab, brings on leading scientists and researchers to explain the actual evidence behind longevity, metabolic health, and healthy aging, not the headlines about it. New episodes weekly. The views, opinions, and stories Chris Wharton shares on The LIVING Room are his own and don’t necessarily reflect the official positions of The WNDR Lab. This podcast is a space for candid, personal conversation, not company communications. Nothing said here constitutes medical advice, a statement of clinical efficacy, or an official company claim about our products or outcomes. Subscribe for more conversations on the real science of longevity, and drop your biggest question about GLP-1 drugs in the pinned comment. Want to learn more? Each month, we send a newsletter curated by our scientific council on what’s actually advancing the science of human longevity, and what isn’t. Subscribe at https://www.thewndrlab.com/mailing-list